TDMS Study 96007-01 Pathology Tables
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/14/02
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 15:44:51
53 WEEK SSAC
Facility: Battelle Columbus Laboratory
Chemical CAS #: 57465-28-8
Lock Date: 01/09/01
Cage Range: All
Reasons For Removal: 25017 Scheduled Sacrifice
Removal Date Range: 02/25/99 - 02/26/99
Treatment Groups: Include 001 0 NG/KG
Include 002 10 NG/KG
Include 003 30 NG/KG
Include 004 100 NG/KG
Include 005 175 NG/KG
Include 006 300 NG/KG
Include 007 550 NG/KG
Include 008 1000 NG/KG
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/14/02
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 15:44:51
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 10 NG/KG 30 NG/KG 100 175 300
NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 48 98 98 98 98
Scheduled Sacrifice 13 15 13 13 13 13
Early Deaths
Survivors
Animals Examined Microscopically 8 8 8 8 8 8
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (8) (8) (8) (8) (8) (8)
Basophilic Focus 2 2 1 2
Cholangiofibrosis 1 [1.0]
Clear Cell Focus 1
Clear Cell Focus, Multiple 1
Eosinophilic Focus 1
Eosinophilic Focus, Multiple 1
Fatty Change, Diffuse 2 [1.0]
Hepatocyte, Multinucleate 1 [1.0]
Inflammation 8 [1.1] 8 [1.0] 8 [1.1] 8 [1.0] 8 [1.1] 8 [1.3]
Mixed Cell Focus 3 3 1 3 2
Mixed Cell Focus, Multiple 1 2 2 6 3 4
Necrosis 1 [2.0]
Pigmentation 3 [1.0] 8 [1.0] 7 [1.1] 8 [1.3]
Toxic Hepatopathy 1 [1.0]
Bile Duct, Cyst 1 [2.0]
Bile Duct, Hyperplasia 1 [1.0]
Hepatocyte, Hypertrophy 3 [1.0] 2 [1.0] 5 [1.2] 6 [1.0] 7 [1.0]
Pancreas (8) (8) (7) (8) (8) (8)
Inflammation, Chronic Active 1 [1.0]
Acinus, Atrophy 1 [1.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (8) (8) (8) (8) (8) (8)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/14/02
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 15:44:51
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 10 NG/KG 30 NG/KG 100 175 300
NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Degeneration, Cystic 1 [2.0]
Hyperplasia 1 [2.0] 1 [1.0] 3 [1.3] 1 [1.0] 1 [2.0]
Hypertrophy 5 [1.4] 6 [1.7] 3 [1.0] 3 [1.0] 1 [1.0] 4 [1.5]
Vacuolization Cytoplasmic 1 [1.0] 1 [1.0]
Pituitary Gland (8)
Pars Distalis, Hyperplasia 2 [1.5]
Thyroid Gland (8) (3) (1) (3) (3) (3)
C-Cell, Hyperplasia 2 [1.5]
Follicular Cell, Hypertrophy 1 [1.0] 3 [1.3] 1 [1.0] 3 [1.0] 3 [1.0] 3 [1.0]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (8) (8) (8) (8) (8) (8)
Atrophy 8 [4.0] 7 [4.0] 7 [4.0] 8 [4.0] 6 [4.0] 8 [4.0]
Cyst 1 [3.0]
Uterus (8) (2) (2)
Inflammation, Suppurative 3 [1.0] 2 [1.5] 2 [2.0]
Metaplasia, Squamous 8 [2.8] 1 [2.0] 2 [3.0]
Endometrium, Hyperplasia, Cystic 2 [3.5] 1 [4.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Spleen (8)
Pigmentation 8 [1.0]
Thymus (8) (8) (8) (8) (7) (8)
Atrophy 7 [2.0] 5 [2.2] 6 [2.0] 5 [2.2] 5 [2.2] 7 [2.4]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (8) (1) (2)
Galactocele 1 [1.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/14/02
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 15:44:51
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 10 NG/KG 30 NG/KG 100 175 300
NG/KG NG/KG NG/KG
____________________________________________________________________________________________________________________________________
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (8) (8) (8) (8) (8) (8)
Infiltration Cellular, Histiocyte 3 [1.0] 4 [1.0] 6 [1.0] 5 [1.0] 4 [1.0] 2 [1.0]
Inflammation, Chronic Active 1 [3.0] 1 [2.0]
Alveolar Epithelium, Metaplasia, Bronchiolar 1 [1.0] 1 [1.0]
Interstitium, Inflammation 1 [1.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
None
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/14/02
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 15:44:51
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 550 1000
NG/KG NG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 98
Scheduled Sacrifice 13 13
Early Deaths
Survivors
Animals Examined Microscopically 8 8
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (8) (8)
Basophilic Focus 1 2
Cholangiofibrosis 1 [2.0]
Clear Cell Focus 1
Eosinophilic Focus, Multiple 1 3
Fatty Change, Diffuse 1 [1.0] 8 [1.0]
Fatty Change, Focal 1 [1.0]
Hepatocyte, Multinucleate 3 [1.0] 8 [2.0]
Inflammation 8 [1.6] 8 [1.6]
Mixed Cell Focus 1
Mixed Cell Focus, Multiple 7 8
Necrosis 1 [1.0]
Pigmentation 8 [1.8] 8 [2.4]
Toxic Hepatopathy 4 [1.3] 8 [2.5]
Vacuolization Cytoplasmic 1 [1.0]
Bile Duct, Hyperplasia 4 [1.0] 6 [1.3]
Hepatocyte, Hypertrophy 8 [1.5] 8 [2.8]
Pancreas (8) (8)
Inflammation, Chronic Active 1 [1.0]
Acinus, Atrophy 1 [1.0]
Acinus, Vacuolization Cytoplasmic 1 [1.0] 6 [1.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (8) (8)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/14/02
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 15:44:51
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 550 1000
NG/KG NG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Atrophy 1 [2.0]
Degeneration, Cystic 2 [1.5]
Hyperplasia 2 [2.5] 3 [2.3]
Hypertrophy 5 [1.2] 5 [1.8]
Thyroid Gland (2) (8)
Follicular Cell, Hypertrophy 2 [1.5] 5 [1.2]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (8) (8)
Atrophy 7 [4.0] 7 [3.9]
Cyst 1 [2.0] 1 [2.0]
Uterus (8)
Inflammation, Suppurative 1 [2.0]
Metaplasia, Squamous 7 [2.0]
Cervix, Cyst 1 [3.0]
Endometrium, Hyperplasia, Cystic 1 [3.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Spleen (1) (8)
Infarct 1 [3.0]
Pigmentation 1 [1.0] 8 [1.0]
Thymus (8) (7)
Atrophy 8 [3.3] 7 [3.7]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (1) (8)
Hyperplasia 1 [2.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 96007-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/14/02
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB-126) Time: 15:44:51
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 550 1000
NG/KG NG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (8) (8)
Infiltration Cellular, Histiocyte 3 [1.0] 6 [1.0]
Alveolar Epithelium, Metaplasia, Bronchiolar 2 [1.0] 6 [1.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
None
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------